摘要
目的观察黄杨宁对冠心病心衰患者血浆氮末端脑钠肽前体(NT-proBNP)水平及运动耐量的影响。方法入选冠心病心衰患者112例,随机分为常规治疗组和黄杨宁组,黄杨宁组在常规治疗基础上加用黄杨宁片,2 mg.次-1,3次.d-1。于开始治疗前及药物治疗6个月后测定NT-proBNP,并行超声心动图检查和6 min步行试验。结果黄杨宁组在治疗后同治疗前及与常规治疗组相比,NT-proBNP水平明显下降(P<0.05),LVEDV明显缩小,而LVEF显著增加(P<0.05),6 min步行距离显著增加(P<0.05)。结论黄杨宁可改善冠心病心衰患者运动耐量,有效降低血浆NT-proBNP水平。
Objective To observe the effect of cyclovirobuxine D on plasma N-terminal pro-brain natriuretic peptide （NT-proBNP） level and exercise tolerance in patients with congestive myocardial failure caused by coronary heart disease. Methods A total of 112 patients with congestive myocardial failure caused by coronary heart disease were selected randomly to a cyclovirobuxine D group and a routine therapy group. The level of NT-proBNP, 2-dimensional echo- cardiography （2DE）, and 6-mintute walk distance were measured for all patients at baseline, 6 months after given cyclovirobuxine D, and routine therapy. Results After given cyclovirobuxine D, the levels of NT-proBNP and LVEDV significantly decreased （P〈20.05）, but LVEF increased （P〈0.05）, and the mean distance of 6-minute walk test significantly increased （P〈0.05） in the cyclovirobuxine D group as compared with that of the routine therapy group. Conclusion Cyclovirobuxine D could treat patients with congestive myocardial failure caused by coronary heart disease and significantly attenuate the increase in NT-proBNP.
出处
《中南药学》
CAS
2009年第4期308-310,共3页
Central South Pharmacy
关键词
脑钠肽
冠状动脉疾病
心力衰竭
黄杨宁
brain natriuretic peptide
coronary disease
myocardial failure
cyclovirobuxine D
